TVTX Q1 2024 Earnings — Travere Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

TVTXTravere Therapeutics, Inc.

$3B

Q1 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$41M-27.4% YoY

Gross Profit

$40M96.4% margin

Operating Income

-$139M-336.5% margin

Net Income

-$136M-328.9% margin

EPS (Diluted)

$-1.76

QoQ Revenue Growth

-8.2%

Cash Flow

Operating Cash Flow

-$119M

Free Cash Flow

-$125M

Stock-Based Comp.

$10M

Balance Sheet

Total Assets

$664M

Total Liabilities

$589M

Stockholders' Equity

$74M

Cash & Equivalents

$43M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$41M	$57M	-27.4%
Gross Profit	$40M	$52M	-23.1%
Operating Income	-$139M	-$80M	-73.4%
Net Income	-$136M	-$86M	-57.6%

Revenue Segments

Product

$40M97%

License

$1M3%